Latest Headlines

  1. Ribo Announces Strategic Collaboration With Insilico Medicine To Accelerate siRNA Drug Development Driven By AI 5/12/2026

    Suzhou Ribo Life Science Co., Ltd. announced that the Company has entered into a strategic collaboration agreement with Insilico Medicine.

  2. Kelun-Biotech Receives Investigational New Drug Approval From CDE For SKB118, A PD-1 x VEGF Bispecific Antibody 5/12/2026

    Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for PD-1 x VEGF bispecific antibody SKB118 (also known as CR-001) for the treatment of advanced solid tumors.

  3. Partner Therapeutics Announces FDA Approval Of BIZENGRI® (Zenocutuzumab-zbco) For NRG1 Fusion-Positive Cholangiocarcinoma Following Receipt Of FDA Commissioner's National Priority Voucher 5/11/2026

    Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has approved BIZENGRI (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.

  4. ACROBiosystems Launches Global License Solution Upgrade For HEK293 Functional Cell Lines, Streamlining Compliance To Accelerate Biopharmaceutical R&D 5/11/2026

    ACROBiosystems announced a major upgrade to its global license solution for HEK293 functional cell lines.

  5. Harbour BioMed Announces U.S. FDA IND Clearance For HBM7004 For The Treatment Of Advanced Solid Tumors 5/8/2026

    Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for HBM7004, enabling the initiation of a first-in-human (FIH) Phase I clinical trial.

  6. LenioBio And Twist Bioscience Enter Into A Collaboration To Further Enable AI Drug-Discovery 5/8/2026

    LenioBio GmbH, a TechBio company commercializing its ALiCE cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation.

  7. Altasciences And Certara Announce Strategic Partnership To Accelerate Early Drug Development 5/7/2026

    Altasciences, a fully integrated drug development solution company, and Certara, a global leader in model-informed drug development (MIDD), today announced a strategic partnership to accelerate early-phase development programs.

  8. USF Scientists Examine AI's Real-World Readiness For Drug Discovery 5/6/2026

    AI is increasingly used by scientists to help advance drug discovery and search for new treatments. But for AI tools to work effectively, researchers need to know whether they can be validated and applied in real-world situations.

  9. InnoCare Announces Approval Of Clinical Trial Of Novel CDH7 Targeted ADC ICP-B208 In China 5/6/2026

    InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a clinical trial of its novel CDH17 targeted ADC, ICP-B208.

  10. Waiv Enters Collaboration With Daiichi Sankyo To Deliver AI-Derived Biomarkers For ADC Program 5/6/2026

    Waiv, formerly Owkin Dx, a Paris-based company catalyzing AI precision testing, today announced it has entered a collaboration with Daiichi Sankyo to lead digital pathology biomarker discovery for an antibody-drug conjugate (ADC) program.